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ABSTRACT
Colorectal cancer (CRC) is a serious public health problem and non-invasive
biomarkers improving diagnosis or therapy are strongly required. Circulating cell-free
DNA (cfDNA) has been a promising target for this purpose. In this study, we evaluated
the potential of long interspersed nuclear element-1 (LINE-1) hypomethylation as
a blood biomarker for CRC. LINE-1 hypomethylation level in plasma cfDNA in 114
CRC patients was retrospectively examined by absolute quantitative analysis of
methylated alleles real-time PCR, and was expressed using LINE-1 hypomethylation
index (LHI) [unmethylated copy number/ (methylated copy number + unmethylated
copy number)]. Greater LHI values indicated enhanced hypomethylation. In our
clinicopathological analysis, CRC patients with large tumors (≥6.0 cm), advanced
N stage (≥2), and distant metastasis (M1) had statistically significantly higher
cfDNA LHI than other CRC patients, suggesting cfDNA LHI as a disease progression
biomarker for CRC. Furthermore, early stage I/II (n = 57) as well as advanced
stage III/IV (n =57) CRC patients had significantly higher cfDNA LHI than healthy
donors (n=53) [stage I/II: median 0.369 (95% confidence interval, 0.360–0.380)
vs. 0.332 (0.325–0.339), P < 0.0001; stage III/IV: 0.372 (0.365–0.388) vs. 0.332
(0.325–0.339), P < 0.0001]. The receiver operating characteristic analysis showed
that cfDNA LHI had the detection capacity of CRC with area under the curve(AUC) of
0.79 and 0.83 in stage I/II and stage III/IV CRC patients, respectively. The present
study demonstrated for the first time the potential of plasma cfDNA LHI as a novel
biomarker for CRC, particularly for early stage detection.

target for cancer biomarker studies. Clinical application of
tumor-related cfDNA in plasma or serum has been termed
“liquid biopsy” and utilized as a non-invasive method
for the detection of tumor specific genetic and epigenetic
alterations [2–5].
Aberrant DNA hypomethylation is one of the major
DNA methylation abnormalities in cancer. It generally
occurs in repetitive transposable DNA elements such
as long interspersed nuclear element-1 (LINE-1) as
well as short interspersed nucleotide elements (SINE or
ALU), and is associated with genomic instability [6].
In particular, highly repetitive sequences of non-coding

INTRODUCTION
Colorectal cancer (CRC) is a serious public health
problem third leading cause of cancer-related deaths
worldwide, owing to its high incidence and cancerrelated mortality [1]. A wide range of biomarkers, such
as those for early detection, tumor progression, prediction
of prognosis, and therapeutic monitoring have been
investigated in the pursuit of the overall improvement of
CRC patients’ outcomes.
In recent years, tumor-related circulating cell-free
DNA (cfDNA) in plasma and serum has been a promising
www.impactjournals.com/oncotarget
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genomic LINE-1 retrotransposon comprise approximately
17–18% of the human genome, therefore, the methylation
status of LINE-1 is considered to be an excellent indicator
of the global DNA methylation status [7]. Many epigenetic
studies have reported the LINE-1 hypomethylation in
various cancers including CRC [8–12], breast cancer [13],
gastric cancer [14, 15], melanoma [16], and hepatocellular
carcinoma (HCC) [17]. In fact, previous studies have
reported a correlation between the presence of LINE-1
hypomethylation in CRC tissue with tumor progression
[12] and poor prognosis [8, 9, 11, 18, 19].
Based on the data presented by Hoshimoto
et al., increased levels of LINE-1 hypomethylation were
observed in the serum cfDNA of stage III or IV malignant
melanoma patients, compared to healthy donors [16].
Nonetheless, the LINE-1 hypomethylation status in plasma
or serum cfDNA from CRC patients has not been further
investigated. In this study, using absolute quantitative
analysis of methylated alleles (AQAMA) real-time PCR
method, we quantified LINE-1 hypomethylation level
in plasma cfDNA from 114 CRC patients, and analyzed
the association with various clinicopathological factors.
Moreover, based on our previous finding of LINE-1
hypomethylation manifestation at very early stages of
CRC development [12], we hypothesized that LINE-1
hypomethylation can be a novel biomarker for early CRC
detection. To that end, we evaluated the potential of LINE1 hypomethylation in plasma cfDNA as a blood biomarker
for early stage CRC detection.

and carbohydrate antigen 19-9 (CA 19-9) levels, T stage
and N stage.
Although no correlation was observed between
cfDNA LHI and T stage when looking at cfDNA LHI,
patients with tumors larger than 6.0 cm had significantly
higher cfDNA LHI than patients with tumors smaller than
6.0cm [0.385 (0.365–0.407) vs. 0.368 (0.362–0.374),
P = 0.04]. In addition, patients with advanced N stage
(≥2) and distant metastasis (M1) had significantly higher
cfDNA LHI [N stage, 0.389 (0.371–0.411) vs. 0.368
(0.357–0.373), P = 0.01; M stage, 0.388 (0.373–0.402) vs.
0.368 (0.360–0.373), P = 0.03]. No correlation was found
between cfDNA LHI and standard prognostic factors for
CRC; tumor location, tumor differentiation, lymphatic
invasion, venous invasion, and preoperative CEA and
CA19-9 blood levels.

Comparison of demographic factors between
healthy donors and CRC patients
We compared demographic factors (sex, age, BMI,
and smoking status) between healthy donors (n = 53)
and CRC patients (n = 114). As shown in Table 2, CRC
patients were significantly older (P < 0.0001) than healthy
donors and had a slightly higher rate of current smokers
(P = 0.07), suggesting that age and smoking status may
be potential confounding factors in our cohort. However,
stratification analysis showed that in both healthy and CRC
patients, neither cfDNA concentration nor cfDNA LHI
were associated with all demographic factors including
age and smoking status (Table 3). Based on these results,
we included all healthy donors and CRC patients into our
subsequent analysis.

RESULTS
Association between clinicopathological factors,
cfDNA concentration and cfDNA LHI in CRC
patients

Comparison of cfDNA concentration and cfDNA
LHI between healthy donors and CRC patients

Plasma cfDNA concentration and cfDNA LINE1 hypomethylation levels in 114 CRC patients who
underwent surgical resection at The University of
Tokyo Hospital between April 2012 and June 2014 were
analyzed. The LINE-1 hypomethylation levels were
evaluated by a modified absolute quantitative analysis of
methylated alleles (AQAMA) real-time PCR assay, which
were validated in our previous studies [12, 13, 16, 20], and
was expressed as LINE-1 hypomethylation index (LHI);
greater LHI indicated enhanced hypomethylation.
Table 1 exhibits the associations between clinicopathological features and both cfDNA concentration and
cfDNA LHI. For cfDNA concentration, CRC patients with
distant metastasis (M1) had significantly higher cfDNA
concentration than those without distant metastasis (M0)
[11.7 (11.1–15.1) vs. 10.2 (8.8–11.5) ng/mL, P = 0.03].
No statistically significant correlations were found
between cfDNA concentration and tumor size, tumor
location, tumor differentiation, lymphatic invasion, venous
invasion, preoperative carcinoembryonic antigen (CEA)
www.impactjournals.com/oncotarget

Figure 1 shows that cfDNA concentration and
cfDNA LHI of CRC patients were significantly higher
than those of healthy donors [cfDNA concentration, 11.1
(9.8–11.6) vs. 7.7 (7.0–9.5) ng/mL, P = 0.0003, Figure 1A;
cfDNA LHI, 0.371 (0.365–0.376) vs. 0.332 (0.325–0.339),
P < 0.0001, Figure 1B].
Next we stratified CRC patients into early
(stage I/II, n = 57) and advanced (stage III/IV, n = 57)
groups. As shown in Figure 2, early stage I/II CRC
patients had significantly higher cfDNA concentration
and cfDNA LHI than healthy donors (n=53) [cfDNA
concentration, 9.8 (8.6–11.5) vs. 7.7 (7.0–9.5) ng/mL,
P = 0.03, Figure 2A; cfDNA LHI, 0.369 (0.360–0.380)
vs. 0.332 (0.325–0.339), P < 0.0001, Figure 2B].
Similarly, advanced stage III/IV CRC patients had
significantly higher cfDNA concentration and cfDNA
LHI [cfDNA concentration, 11.5 (11.0–13.0) vs. 7.7
(7.0–9.5) ng/mL, P = 0.0006, Figure 2A; cfDNA
LHI, 0.372 (0.365–0.388) vs. 0.332 (0.325–0.339),
11907
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Table 1: Clinicopathological factors and cfDNA concentration and cfDNA LHI in CRC patients (n = 114)
Factors

Number (%)

cfDNA concentration,
median (95% CI), ng/
mL

Tumor size

P value

cfDNA LHI, median (95%
CI)

0.64

0.04

<6.0 cm

85 (74.6%)

10.7 (9.6–11.7)

0.368 (0.362–0.374)

≥6.0 cm

29 (25.4%)

11.1 (9.1–14.5)

0.385 (0.365–0.407)

Location

0.08

0.77

Right-side

34 (29.8%)

11.8 (9.8–16.6)

0.372 (0.36–0.388)

Left-side

80 (70.2%)

10.4 (8.9–11.4)

0.371 (0.362–0.382)

Tumor differentiation

0.75

0.52

WD

46 (40.4%)

10.9 (8.9–11.9)

0.373 (0.362–0.382)

MD

60 (52.6%)

11.2 (9.1–12.6)

0.369 (0.357–0.384)

8 (7.0%)

10.6 (8.2–37.5)

0.387 (0.350–0.440)

PD/Mucinous
Lymphatic invasion

0.97

0.54

Negative

69 (60.5%)

10.5 (9.6–11.7)

0.373 (0.365–0.383)

Positive

45 (39.5%)

11.5 (8.4–12.6)

0.370 (0.352–0.377)

Venous invasion

0.72

0.86

Negative

25 (21.9%)

10.4 (8.1–12.6)

0.372 (0.361–0.376)

Positive

89 (78.1%)

11.1 (9.8–11.8)

0.371 (0.362–0.383)

Preoperative CEA

0.17

0.57

<5.0 ng/mL

52 (45.6%)

10.3 (8.2–11.5)

0.368 (0.364–0.382)

≥5.0 ng/mL

62 (54.4%)

11.3 (9.8–12.8)

0.373 (0.365–0.388)

Preoperative CA19-9

0.28

0.49

<37 ng/mL

83 (72.8%)

10.4 (8.9–11.6)

0.371 (0.363–0.383)

≥37 ng/mL

31 (27.2%)

11.4 (9.4–15.1)

0.372 (0.349–0.381)

T stage

0.57

0.69

T1–2

28 (24.6%)

10.1 (8.1–11.6)

0.372 (0.363–0.382)

T3–4

86 (75.4%)

11.2 (9.8–11.9)

0.371 (0.360–0.383)

N stage

0.61

0.01

N0–1

90 (78.9%)

10.6 (9.4–11.5)

0.368 (0.357–0.373)

N2–3

24 (21.1%)

11.6 (8.9–15.1)

0.389 (0.371–0.411)

M stage

P value

0.03

0.03

M0

87 (76.3%)

10.2 (8.8–11.5)

0.368 (0.360–0.373)

M1

27 (23.7%)

11.7 (11.1–15.1)

0.388 (0.373–0.402)

Abbreviations: cfDNA, circulating cell-free DNA; LHI, LINE-1 hypomethylation index; CRC, colorectal cancer;
CI, confidence interval; WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated; CEA,
carcinoembryonic antigen; CA 19-9, carbohydrate antigen 19-9.
P < 0.0001, Figure 2B] than healthy donors. On the
other hand, there were no statistically significant
differences in cfDNA concentrations and cfDNA
www.impactjournals.com/oncotarget

LHI between early and advanced stage CRC patients
(cfDNA concentration, P = 0.31, Figure 2A; cfDNA
LHI, P = 0.66, Figure 2B).
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Table 2: Comparison of demographic factors between healthy donors and CRC patients
Factors

Healthy donors
(n = 53)

P value

CRC patients
(n =114)

Sex

0.38

  Male

34 (64.1%)

65 (57.0%)

  Female

19 (35.9%)

49 (43.0%)

Age

50.6 (SD 19.3)

63.0 (SD 12.5)

< 0.0001

BMI

22.5 (SD 2.5)

22.2 (SD 3.3)

0.43

Smoking status

0.07

  Current

7 (13.2%)

29 (25.4%)

  Former/None

46 (86.8%)

85 (74.6%)

Abbreviations: CRC, colorectal cancer; BMI, body mass index; SD, standard deviation.

Table 3: Demographic factors and cfDNA concentration and cfDNA LHI in healthy donors and CRC patients
Factors

Healthy donors (n =53)
Number
cfDNA
P
(%)
concentration value

Sex

cfDNA LHI

0.32

CRC patients (n = 114)
P Number
cfDNA
value (%)
concentration

P
value

0.32

0.97

cfDNA LHI

0.11

Male

34 (64%) 8.0 (6.4–12.2)

0.331
(0.324–0.337)

65 (57%) 11.1 (9.1–11.7)

0.365 (0.357–0.374)

Female

19 (36%)

0.334
(0.320–0.345)

49 (43%) 11.1 (8.9–12.8)

0.373 (0.370–0.391)

7.7 (7.0–9.3)

Age

0.93

0.48

0.15

0.96

<60 years 34 (64%) 8.3 (4.9–10.4)

0.331
(0.315–0.344)

44 (39%) 9.7 (8.2–11.2)

0.372 (0.360–0.383)

≥60 years 19 (36%) 7.2 (6.6–10.0)

0.334
(0.325–0.344)

70 (61%) 11.5 (10.0–12.7)

0.371 (0.362–0.381)

BMI

0.80

0.52

0.51

0.27

<25

45 (85%)

7.7 (6.4–9.5)

0.334
(0.325–0.340)

89 (78%) 11.1 (9.8–11.5)

0.373 (0.365–0.383)

≥25

8 (15%)

7.1 (6.6–23.9)

0.327
(0.316–0.355)

25 (22%) 11.7 (7.7–15.7)

0.367 (0.350–0.374)

Smoking
Current
 Former/
None

0.23

0.30

0.48

0.41

7 (13%) 10.6 (2.26–23.9)

0.326
(0.285–0.349)

29 (25%) 11.1 (7.7–12.6)

0.373 (0.360–0.389)

46 (87%)

0.334
(0.325–0.340)

85 (75%) 11.1 (9.8–11.9)

0.370 (0.362–0.376)

7.6 (7.0–9.3)

P
value

Note: cfDNA concentration and cfDNA LHI were expressed as median (95% confidence interval).
Abbreviations: cfDNA, circulating cell-free DNA; LHI, LINE-1 hypomethylation index; CRC, colorectal cancer; BMI, body mass index.

ROC curve analysis for the detection capacity of
CRC

patients from healthy donors using receiver operating
characteristic (ROC) curve analysis. The optimal cutoff values were determined from the highest Youden
index [21]. Using the cut-off value of 0.360, cfDNA
LHI distinguished CRC patients with 65.8% sensitivity

We examined the capacity of cfDNA concentration
and cfDNA LHI as a biomarker for distinguishing CRC
www.impactjournals.com/oncotarget
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DISCUSSION

and 90.0% specificity (area under the curve (AUC) 0.81,
P < 0.0001, Figure 3A). Next we performed subgroup
analysis for early (stage I/II) and advanced (stage III/
IV) CRC patients. cfDNA LHI distinguished early CRC
patients with 63.2% sensitivity and 90.0% specificity
(AUC 0.79, P < 0.0001, Figure 3B) and advanced CRC
patients with 68.4% sensitivity and 90.0% specificity
(AUC 0.83, P < 0.0001, Figure 3C).
Using the cut-off value of 10.7 ng/mL, cfDNA
concentration distinguished early CRC patients
with 42.1% sensitivity and 75.0% specificity (AUC
0.64, P = 0.03) and advanced CRC patients with 63.2%
sensitivity and 75.0% specificity (AUC 0.70, P = 0.003),
rendering it less adequate for CRC detection than cfDNA
LHI.

In this study, we examined 114 plasma samples of
CRC patients, and quantified LINE-1 hypomethylation
status in plasma cfDNA by AQAMA PCR method.
The efficacy of this assay has been validated in several
previous studies [12, 13, 16, 20]. We confirmed that even
early stage I/II as well as advanced stage III/IV CRC
patients had significantly higher cfDNA LHI than healthy
donors. Detection of early stage I/II CRC through cfDNA
LHI was accomplished with 63.2% sensitivity and 90.0%
specificity (AUC 0.79), suggesting the potential utility of
cfDNA LHI as a blood biomarker for early CRC detection.
Colonoscopy is the gold standard for CRC
diagnosis, given its more than 90% sensitivity and
specificity [22]. However, due to its invasive nature and
possible morbid complications such as bowel perforation,
most patients are reluctant to undergo colonoscopy.
At present, fecal occult blood test (FOBT) is the most
frequently used non-invasive modality in CRC screening
program in the USA. Prospective randomized controlled
trials showed that FOBT screening reduced CRC-related
mortality [23]. Furthermore, recent fecal immunochemical
test (FIT) has shown high CRC detectability [24], while
the utility of stool-based DNA assays has been reported as
a new application for CRC diagnosis [25]. Nonetheless,
FOBT has some limitations, such as its relatively low

Comparison of sensitivity between CEA and
cfDNA LHI for CRC detection
We assessed the capacity of a standard blood CEA
biomarker for CRC detection in CRC patients. Table 4
shows that the sensitivity of CEA for CRC detection
was 40.4% in stage I/II CRC with the conventional
cut-off value of 5.0 ng/mL. On the other hand, the
sensitivity of cfDNA LHI was 63.2% in stage I/II CRC,
indicating its higher sensitivity for early CRC detection
than CEA.

Figure 1: Comparison of cfDNA concentration and cfDNA LHI between healthy donors and CRC patients. A. cfDNA

concentration of 114 CRC patients was significantly higher than that of 53 healthy donors (Mann–Whitney U test, P = 0.0003). B. cfDNA
LHI of 114 CRC patients was significantly higher than that of 53 healthy donors (Mann–Whitney U test, P < 0.0001). The horizontal line
represents the median value.
www.impactjournals.com/oncotarget
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sensitivity for early-stage or proximal colon cancer [24,
26]. Moreover, adherence rate to the CRC screening
program based on FOBT and colonoscopy remains low at
around 50% [27, 28], and it is reported that many people

who avoid current FOBT program prefer a simple bloodbased test instead [29]. Our non-invasive blood-based
method would be particularly beneficial for patients who
are averse to stool-based test.

Figure 2: Comparison of cfDNA concentration and cfDNA LHI between healthy donors and early (stage I/II) and
advanced (stage III/IV) CRC patients. A. A nonparametric multiple comparison Steel-Dwass test showed that both early stage I/II
and advanced stage III/IV CRC patients had significantly higher cfDNA concentration than healthy donors [stage I/II, 9.8 (8.6–11.5) vs.
7.7 (7.0–9.5) ng/mL, P = 0.03; stage III/IV, 11.5 (11.0–13.0) vs. 7.7 (7.0–9.5) ng/mL, P = 0.0006]. There was no statistically significant
difference of cfDNA concentration between early and advanced CRC patients (P = 0.31). The horizontal line represents the median value.
B. A nonparametric multiple comparison Steel-Dwass test showed that both early stage I/II and advanced stage III/IV CRC patients had
significantly higher cfDNA LHI than healthy donors [stage I/II, 0.369 (0.360–0.380) vs. 0.332 (0.325–0.339), P < 0.0001; stage III/IV,
0.372 (0.365–0.388) vs. 0.332 (0.325–0.339), P < 0.0001]. There was no statistically significant difference of cfDNA LHI between early
and advanced CRC patients (P = 0.66). The horizontal line represents the median value.

Figure 3: ROC curve analysis assessing the capacity of cfDNA LHI to distinguish CRC patients from healthy donors.
A. ROC curve analysis of cfDNA LHI for all stage CRC patients. Using the cut-off value of 0.360, cfDNA LHI could distinguish CRC
patients with 65.8% sensitivity and 90.0% specificity (AUC 0.81, P < 0.0001). The optimal cut-off value was defined as the highest Youden
index [(specificity + sensitivity) − 1]. B. ROC curve analysis for early CRC patients (stage I/II). cfDNA LHI showed sensitivity 63.2%,
specificity 90.0% (AUC 0.79, P < 0.0001). C. ROC curve analysis for advanced CRC patients (stage III/IV). cfDNA LHI showed sensitivity
68.4%, specificity 90.0% (AUC 0.83, P < 0.0001).
www.impactjournals.com/oncotarget
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Table 4: Comparison of sensitivity between CEA and cfDNA LHI for CRC patients
All stage
(n = 114)

Stage I/II
(n = 57)

Stage III/IV
(n= 57)

54.4% (62/114)

40.4% (23/57)

68.4% (39/57)

65.8% (75/114)

63.2% (36/57)

68.4% (39/57)

CEA (≥5.0 ng/mL)
  Sensitivity
cfDNA LHI
  Sensitivity

Abbreviations: cfDNA, circulating cell-free DNA; LHI, LINE-1 hypomethylation index; CRC, colorectal cancer; CEA,
carcinoembryonic antigen.
Most blood methylation biomarkers target a single
chromosome region. As a result, the amount of target
cfDNA fragments in blood circulation can be very
limited particularly after bisulfite conversion [30], raising
concerns about false negative results. To increase the
assay sensitivity, a large amount of plasma is sometimes
needed; commercially offered mSEPT9 test such as Epi
proColon (Epigenomics AG, Berlin, Germany) requires
3.5 mL of plasma [31]. Conversely, the abundant number
of LINE-1 copies in the human genome enabled us to
quantify the absolute methylation level with 0.5 mL of
plasma without any additional applications such as digital
PCR or next generation sequencing. Moreover, our LINE1 assay is particularly advantageous when using plasma,
which is preferred due to its relatively low genomic DNA
contamination, but has lower amount of cfDNA than
serum [3].
Although the sensitivity and specificity of CEA are
considered to be insufficient for CRC detection, CEA is the
most routinely measured blood biomarker for CRC. Our
data showed that cfDNA LHI had higher sensitivity for early
stage I/II CRC than CEA. In a recent systematic review [32],
the pooled specificity of CEA for CRC detection was 88.0%
with the conventional cut-off value of 5.0 ng/mL, which
is similar to our results’ specificity of 90.0%, suggesting
cfDNA LHI to be more suitable for early CRC detection than
CEA. Several previous studies have also reported the utility
of simple quantitative assessment of cfDNA concentration
for CRC diagnosis [33–36]. However, in our cohort, cfDNA
concentration demonstrated lower detectability of CRC
when compared to cfDNA LHI.
Additionally, considering that cfDNA concentration
can be affected by various non-malignant diseases
and physiological conditions [3], its diagnostic utility
for CRC is further discredited. We did not observe a
statistically significant difference in cfDNA LHI and
cfDNA concentrations between early (stage I/II) and
advanced (stage III/IV) CRC patients. Although LINE1 hypomethylation occurs at very early stage in CRC
development [12], several studies have reported that
LINE-1 hypomethylation status in CRC tissue was
independent of CRC stage [8, 11, 37, 38]. Overall, LINE1 hypomethylation is believed to remain relatively stable
www.impactjournals.com/oncotarget

during CRC progression [39]. These findings may partially
explain our results that no difference of cfDNA LHI was
observed between early and advanced CRC patients. On
the other hand, CRC patients with highly advanced stage
(N ≥2 and M1) and large tumor size (≥6.0 cm) showed
significantly higher cfDNA LHI than other patients in
the study, implying the possibility of cfDNA LHI as a
biomarker for advanced CRC progression and/or distant
metastasis.
Four limitations of this study must be noted.
First, LINE-1 hypomethylation in plasma cfDNA is not
always specific to CRC. Similar to other methylation
blood biomarkers, no CRC-specific DNA methylation
biomarkers have been identified at this time. However,
considering the recent high incidence and cancer-related
mortality of CRC, it may be beneficial to employ our
non-invasive blood assay and easily measure cfDNA
as a first step towards CRC detection and recurrence
after surgery. Repetitive analysis at specific intervals of
cfDNA LHI may also be useful for disease monitoring
as in early detection of recurrence following the surgical
resection of CRC in high risk patients. Second, in
comparison with healthy donors, we assessed four
demographic factors (sex, age, BMI, and smoking
factors) that may influence cfDNA LHI. However, DNA
methylation can also be affected by other factors such
as race, alcohol consumption, physical activity, and diet
[40], whose associations with LINE-1 hypomethylation
remain undetermined [40]. Third, during the median
follow-up of 24.6 months, eight patients died of CRC
(one stage II, one stage III and six stage IV) and 13
patients in stage I–III experienced tumor recurrence after
the curative resection (four stage II and nine stage III).
However, we could not detect a statistically significant
correlation between patients’ prognosis and cfDNA LHI.
This may be due to the short follow-up period. Finally,
this was a prospective pilot study from a single institute
small patient cohort. Therefore, prospective studies and
multi-institutional validation are needed in the future.
In conclusion, the present study is the first report
demonstrating the potential of LINE-1 hypomethylation
in plasma cfDNA as a blood biomarker for CRC detection,
particularly for early stages of the disease.
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MATERIALS AND METHODS

and a Quani-iT PicoGreen dsDNA Assay Kit (Life
Technologies) according to the manufacturer’s instructions.

Patients and healthy donors

Sodium bisulfite conversion

We analyzed a total of 114 plasma samples obtained
from consecutive CRC patients who underwent surgical
tumor resection at the University of Tokyo Hospital
between April 2012 and June 2014, whose plasma samples
were available for analysis. Exclusion criteria for this
study consisted of any patients with a history of malignant
disease or colitis associated CRC, as well as patients
receiving any preoperative treatments or radiotherapy.
No other malignant tumors except CRC were found
in patients after preoperative examinations. A detailed
database of clinicopathological information was developed
for statistical analysis. The cancer’s histological grade
and clinical stage were identified in accordance with the
seventh edition of the TNM classification of the Union for
International Cancer Control (UICC).
Fifty-three healthy donors were also analyzed. All
healthy donors were having medical check-ups periodically
and had no history of cancer or bowel symptoms, representing
a normal Japanese adult population cohort at average risk of
CRC. For the healthy donors > 50 yrs, prior to blood sample
collection, colonoscopy examination was performed to
confirm the absence of advanced adenoma or CRC.
The study protocol was approved by the ethics
committee of the University of Tokyo Hospital and written
informed consents were obtained from all participating
patients.

Sodium bisulfite conversion was performed as
previously described [42]. In brief, up to 500 ng of DNA
was denatured in 0.3 M NaOH at 37°C for 15 min and
dissolved in a solution consisting of 3.06 M sodium
bisulfite (Sigma-Aldrich) and 0.5 mM hydroquinone
(Sigma-Aldrich) adjusted to pH 5.0 with NaOH. The
solution was subjected to 15 cycles of denaturation at 95°C
for 30 s and incubation at 50 °C for 15 min, desalted and
desulfonated on a Zymo-Spin Column (Zymo Research),
and eluted with 20 µL of Tris-EDTA buffer.

Measurement of LINE-1 hypomethylation status

Plasma samples were thawed and microcentrifuged
at 4°C and 12,000 g for 3 min to remove cell debris.
cfDNA was extracted from plasma as previously
described [12, 16, 41]. In brief, aliquots of 500 µL plasma
were diluted with 0.9% NaCl and mixed with a premix
consisting of proteinase K and SDS. After incubation at
50°C for 3 h, cfDNA was treated with phenol–chloroformisoamyl alcohol (25:24:1, pH 8.0; Nippon Gene) and
precipitated with isopropanol.

The hypomethylation status of LINE-1 was
evaluated by a modified absolute quantitative analysis
of methylated alleles (AQAMA) assay [12, 13, 16, 20].
In brief, AQAMA requires forward and reverse primers
for amplifying a targeted sequence, methylation-specific
and unmethylation-specific TaqMan probes with minor
groove binder (MGB). The targeted sequence of LINE1 was 148 bp in size and located in the promoter region
of LINE-1. LINE-1 hypomethylation of this targeted
region in early CRC tissue had already been confirmed
in our previous study [12]. Primers and probes were
purchased from Life Technologies. The following sets of
primers were used: forward primer, 5′-GGGTTTATTTT
ATTAGGGAGTGTTAGA-3′; reverse primer, 5′-TCAC
CCCTTTCTTTA ACTCAAA-3′; methylation-specific
probe, VIC-5′-TGCGCGAGTCGAAGT-3′-MGB; and
unmethylation-specific probe, FAM-5′-TGTGTGAGT
TGAAGTAGGG-3′-MGB. The AQAMA PCR reaction
was performed with a 7500 Fast Real-Time PCR system
(Life Technologies). All measurements were taken
in triplicate of 20 µL consisting of 2 µL of bisulfiteconverted DNA template, 10µL of KAPA PROBE FAST
qPCR Master Mix (KAPA Biosystems), 0.4 µmol/L of
the forward and reverse primer, and 0.25µmol/L of each
MGB probe. The PCR conditions were as follows: 95°C
for 3 min, followed by 40 cycles at 95°C for 15 s, and
60°C for 60 s. The absolute copy number of each sample
was estimated from a standard curve with known copy
numbers (10*6 to 10*1 copies).
The LINE-1 hypomethylation index (LHI) was
defined as the unmethylated copy number/ (methylated
copy number + unmethylated copy number), so that a
greater LHI indicated enhanced LINE-1 hypomethylation.
This LHI was used for the analysis.

Measurement of cfDNA concentration

Construction of control plasmid

DNA concentration of each plasma sample was
quantified using Varioskan Flash (ThermoFisher Scientific)

The universal unmethylated and methylated
control DNA was synthesized from peripheral blood

Specimen demographics
Prior to the operation, peripheral blood (10 mL) of
each patient was collected into EDTA-containing blood
tubes. Plasma was obtained by centrifugation of the whole
blood samples at 1,500 g for 10 min and immediately
stored at −80°C until analysis. Similarly, peripheral blood
collection (5mL) of healthy donors was followed by
extraction of plasma and storage as describe above.

cfDNA extraction from plasma
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